iBio, Inc. (IBIO) stock
Close on Nov 12, 2026Market cap $49.02MP/E –Yield –
iBio, Inc. grew revenue 115.0% to $1.08M over the twelve months to Sep 30, 2026. Free cash flow was -$27.59M. At the latest close the market valued the company at $49.02M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $49.02M
- P/E ratio
- –
- Price to sales
- 45.60
- Price to book
- 0.62
- Dividend yield
- –
- Free cash flow yield
- -56.28%
Fundamentals
- Revenue
- $1.08M
- Net income
- -$34.88M
- EPS, diluted
- -$0.27
- Free cash flow
- -$27.59M
- Book value per share
- $0.52
- Diluted shares
- 152M
Trading
- Next earnings
- Feb 9, 2027 (estimated, after the close)
- Previous close
- $0.82
- Open
- $0.83
- Day's range
- $0.76 – $0.83
- Volume
- 300,033
- Average volume (20 days)
- 499,038
- Beta (5 years)
- 1.13
- 52-week range
- $0.69 – $3.82
- RSI (14 days)
- 41.2
- Volatility (1 year)
- 104.5%
- Relative volume
- 0.42×
- WACC
- 10.5%
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | IBIO | S&P 500 | Difference | IBIO per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -15.6% | -2.7% | −12.9 pts | ||
| 3 months | -48.1% | -1.7% | −46.4 pts | ||
| Year to date | -60.5% | +11.9% | −72.4 pts | ||
| 1 year | -39.0% | +12.0% | −51.0 pts | ||
| 3 years | -86.4% | +78.2% | −164.6 pts | -48.6% | +21.2% |
| 5 years | -99.8% | +73.2% | −173.0 pts | -71.1% | +11.6% |
| 10 years | -100.0% | +309.6% | −409.6 pts | -55.1% | +15.1% |
Fifteen years at a glance
Fiscal years 2012 to 2026 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases iBio filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Update
- Results
- News
- Update
About iBio
Pharmaceutical Preparations
iBio, Inc. is a clinical-stage biotechnology company that develops precision antibody therapeutics for obesity, cardiometabolic conditions, and cardiopulmonary diseases. Operating through an integrated artificial intelligence and machine learning drug discovery platform, the company designs biologic candidates directed against complex, hard-to-drug targets. Its pipeline includes IBIO-600, an anti-myostatin antibody in clinical development, alongside preclinical candidates such as IBIO-610, an Activin E antibody, and IBIO-800, a bispecific antibody for cardiopulmonary indications. Additionally, the company develops T-cell engaging bispecific antibodies for oncology and collaborates with partners such as AstralBio on engineered amylin receptor agonist antibodies.
Company profile, executives and historyiBio stock: common questions
What is iBio's stock price?
IBIO closed at $0.76 on Nov 12, 2026, down 7.52% on the day. Over the past 52 weeks it traded between $0.69 and $3.82.
What is iBio's market cap?
iBio was worth $49.02M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is IBIO's P/E ratio?
iBio lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.27), so it has no meaningful P/E ratio.
How much revenue does iBio make?
iBio reported revenue of $1.08M for the twelve months to Sep 30, 2026, up 115.0% from a year earlier.
Does iBio pay a dividend?
No. iBio has not paid a cash dividend over the last twelve months.
When does iBio report earnings next?
iBio is expected to report Q2 FY2027 results on Feb 9, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has IBIO stock performed over the past year?
Including dividends, IBIO returned -39.0% over the past year, against +12.0% for the S&P 500.
How many IBIO shares are sold short?
4M shares were sold short at the latest FINRA report, 6.30% of the float, or 7.2 days of average trading volume.
Who are iBio's competitors?
Companies most similar to iBio by business, industry and size include STTK, CNTB, MNOV, RNAC, RLYB.
See a number that looks wrong?